Comparable stake leader
FEDERATED HERMES, INC.
SEC ownership of Minerva Neurosciences, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001598646.
Disclosed value leader
FEDERATED HERMES, INC.
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Symbol
- NERV on Nasdaq
- SEC evidence covered
- 13D/G, 13F, and 3/4/5
- Largest SEC-reported holder
- FEDERATED HERMES, INC.
- Latest 13D/G holder
- FEDERATED HERMES, INC.
- Latest parsed evidence date
- 31 Mar 2026
- CIK
- 0001598646
- Location
- Burlington, MA
Ownership snapshot
2 signals
Issuer
2 identity fields
Ownership snapshot
Top shareholders of Minerva Neurosciences, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FEDERATED HERMES, INC.
Disclosed value leader
FEDERATED HERMES, INC.
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 20%
13D/G row: FEDERATED HERMES, INC.
Showing 1-8 of 50 holder rows.
Quick read
FEDERATED HERMES, INC. leads the comparable SEC ownership view at 20%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
FEDERATED HERMES, INC.
20%
Vivo Opportunity Fund Holdings, L.P.
10%
BALYASNY ASSET MANAGEMENT L.P.
10%
Coastlands Capital LP
10%
Farallon Capital Partners, L.P.
10%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FEDERATED HERMES, INC. |
13D/G
13F
Company
|
20%
|
$35,502,800
9,392,275 shares
|
+$30,394,980 | 22 Dec 2025 |
| Vivo Opportunity Fund Holdings, L.P. |
13D/G
|
10%
|
$32,476,142
8,591,572 shares
|
$0 | 23 Dec 2025 |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
13D/G
Company
|
10%
from 13D/G
|
$25,658,065
4,258,600 shares
|
— | 31 Mar 2026 |
| Coastlands Capital LP |
13D/G
|
10%
|
$18,571,536
4,563,031 shares
|
$0 | 13 Feb 2026 |
| Farallon Capital Partners, L.P. |
13D/G
Dapice Joshua J.
|
10%
|
$18,250,213
4,539,854 shares
|
$0 | 31 Dec 2025 |
| JANUS HENDERSON GROUP PLC |
13F
13D/G
Company
|
9.9%
from 13D/G
|
$25,872,910
4,294,259 shares
|
— | 31 Mar 2026 |
| Logos Global Management LP |
13F
13D/G
Company
|
9.9%
from 13D/G
|
$19,370,375
3,215,000 shares
|
— | 31 Mar 2026 |
| Adage Capital Management, L.P. |
13D/G
|
6.4%
|
$11,777,700
2,838,000 shares
|
$0 | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 02 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-13 of 13 reporting-owner rows connected to Minerva Neurosciences, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
13
Largest Forms 3/4/5 holder
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Net 12M change
$0
Latest report
21 Apr 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 10%+ Owner | $4,794,000 | Mixed | 27 Jun 2023 | ||
| BARCLAYS PLC | 10%+ Owner | Mixed | 11 Aug 2022 | |||
| Jeryl L. Hilleman | Director | Mixed | 27 Sep 2023 | |||
| David Kupfer | Director | Mixed | 22 Dec 2025 | |||
| Fouzia Laghrissi-Thode | Director | Mixed | 22 Dec 2025 | |||
| Remy Luthringer | CEO, Director | Mixed | 22 Dec 2025 | |||
| Geoff Race | President | Mixed | 22 Dec 2025 | |||
| William F. Doyle | Director | Mixed | 10 Jun 2022 | |||
| Hans Peter Hasler | Director | Mixed | 22 Dec 2025 | |||
| Frederick W. Ahlholm | SVP, CFO and Secretary | Mixed | 22 Dec 2025 | |||
| Inderjit Kaul | Director | Mixed | 31 Mar 2026 | |||
| VAN HEEK G JAN | Director | Mixed | 22 Dec 2025 | |||
| James Joseph O'Connor | Chief Business Officer and GC | Mixed | 21 Apr 2026 |
Recent insider transactions for Minerva Neurosciences, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| James Joseph O'Connor | NERV | Employee Stock Option (right to buy) | Award | 350,800 | 350,800 | 21 Apr 2026 | Direct | |||
| Inderjit Kaul | NERV | Stock Option (right to buy) | Award | 12,169 | 12,169 | 31 Mar 2026 | Direct | |||
| David Kupfer | NERV | Stock Option (right to buy) | Award | 50,000 | 50,000 | 22 Dec 2025 | Direct | |||
| Inderjit Kaul | NERV | Stock Option (right to buy) | Award | 364,504 | 364,504 | 22 Dec 2025 | Direct | |||
| Hans Peter Hasler | NERV | Stock Option (right to buy) | Award | 50,000 | 50,000 | 22 Dec 2025 | Direct | |||
| Fouzia Laghrissi-Thode | NERV | Stock Option (right to buy) | Award | 50,000 | 50,000 | 22 Dec 2025 | Direct | |||
| Van Heek G Jan | NERV | Stock Option (right to buy) | Award | 50,000 | 50,000 | 22 Dec 2025 | Direct | |||
| Frederick W. Ahlholm | NERV | Employee Stock Option (right to buy) | Award | 500,000 | 500,000 | 22 Dec 2025 | Direct | |||
| Geoff Race | NERV | Employee Stock Option (right to buy) | Award | 1,500,000 | 1,500,000 | 22 Dec 2025 | Direct | |||
| Remy Luthringer | NERV | Employee Stock Option (right to buy) | Award | 2,250,000 | 2,250,000 | 22 Dec 2025 | Direct | |||
| Inderjit Kaul | NERV | Stock Option (right to buy) | Award | 9,500 | 9,500 | 14 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.